Empagliflozin (EMPA) as Add-on to Linagliptin (LINA) and Metformin in Patients with Type 2 Diabetes (T2DM): A 24-Week Randomized, Double-Blind, Double-Dummy, Parallel-Group Trial

被引：0
|
作者：
Softeland, Eirik
Meier, Juris J.
Vangen, Bente
Toorawa, Robert
Maldonado, Mario
Woerle, Hans J.
Broedl, Uli C.
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1128-P
引用
收藏
页码：A295 / A295
页数：1
相关论文
共 50 条
  • [21] Safety and Tolerability of Combinations of Empagliflozin/Linagliptin (EMPA/LINA) for 52 Weeks in Subjects with Type 2 Diabetes (T2DM)
    Patel, Sanjay
    Defronzo, Ralph A.
    Lewin, Andrew
    Liu, Dacheng
    Kaste, Renee
    Kohler, Sven
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2015, 64 : A326 - A327
  • [22] Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension
    Jin, S-M
    Park, C-Y
    Cho, Y. M.
    Ku, B. J.
    Ahn, C. W.
    Cha, B-S
    Min, K. W.
    Sung, Y. A.
    Baik, S. H.
    Lee, K. W.
    Yoon, K-H
    Lee, M-K
    Park, S. W.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (06): : 599 - 602
  • [23] Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
    Pan, C.
    Yang, W.
    Barona, J. P.
    Wang, Y.
    Niggli, M.
    Mohideen, P.
    Wang, Y.
    Foley, J. E.
    [J]. DIABETIC MEDICINE, 2008, 25 (04) : 435 - 441
  • [24] Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
    Rosenstock, Julio
    Mills, David
    Baron, Michelle A.
    Schweizer, Anja
    Dejager, Sylvie
    [J]. DIABETES CARE, 2007, 30 (02) : 217 - 223
  • [25] Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study
    Bailey, CJ
    Bagdonas, A
    Rubes, J
    McMorn, SO
    Donaldson, J
    Biswas, N
    Stewart, MW
    [J]. CLINICAL THERAPEUTICS, 2005, 27 (10) : 1548 - 1561
  • [26] Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Taskinen, M. -R.
    Rosenstock, J.
    Tamminen, I.
    Kubiak, R.
    Patel, S.
    Dugi, K. A.
    Woerle, H. -J.
    [J]. DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 65 - 74
  • [27] Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
    Matthaei, Stephan
    Catrinoiu, Doina
    Celinski, Aleksander
    Ekholm, Ella
    Cook, William
    Hirshberg, Boaz
    Chen, Hungta
    Iqbal, Nayyar
    Hansen, Lars
    [J]. DIABETES CARE, 2015, 38 (11) : 2018 - 2024
  • [28] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A291 - A291
  • [29] A Randomized, Double-Blind, Phase 3 Trial of Dapagliflozin Add-on to Saxagliptin plus Metformin in Type 2 Diabetes
    Mathieu, Chantal
    Ranetti, Aurelian E.
    Li, Danshi
    Ekholm, Ella
    Cook, William
    Hirshberg, Boaz
    Hansen, Lars
    Iqbal, Nayyar
    [J]. DIABETES, 2015, 64 : A28 - A28
  • [30] Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial
    Halvorsen, Yuan-Di
    Conery, Annie L.
    Lock, John Paul
    Zhou, Wenjiong
    Freeman, Mason W.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2954 - 2962
12345